Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.51 |
| ▸ | ALB | P02768 | 5/20 | 0.50 |
| ▸ | IL2 | P60568 | 5/20 | 0.50 |
| ▸ | MDM4 | O15151 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030857 | 1.00 | FOLH1 (0.51) | FOLH1ALBIL2MDM4TP53 | |
| SCHEMBL29641557 | 1.00 | FOLH1 (0.51) | FOLH1ALBIL2MDM4TP53 | |
| SCHEMBL24489613 | 1.00 | FOLH1 (0.51) | FOLH1ALBIL2MDM4TP53 | |
| SCHEMBL14584328 | 1.00 | FOLH1 (0.51) | FOLH1ALBIL2MDM4TP53 | |
| SCHEMBL29500417 | 0.91 | PTPN1 (0.54) | MDM4TP53PTPN1MDM2SLC17A5 | |
| SCHEMBL29843110 | 0.91 | PTPN1 (0.54) | MDM4TP53PTPN1MDM2SLC17A5 | |
| SCHEMBL9732381 | 0.91 | PTPN1 (0.54) | MDM4TP53PTPN1MDM2SLC17A5 | |
| Catechol SCHEMBL18074826 | 0.90 | PTPN1 (0.53) | MDM4TP53PTPN1MDM2SLC17A5 | |
| SCHEMBL120691 | 0.90 | MDM4 (0.52) | MDM4TP53PTPN1MDM2SLC17A5 | |
| SCHEMBL29401272 | 0.90 | MDM4 (0.52) | MDM4TP53PTPN1MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352678-A1 | RADIOPHARMACEUTICALS | ADVANCELL IPCO US NO. 1 PTY LTD (AU) | 2025-11-20 | — | — | US | disclosed |
| US-20250319213-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX ADVANCED BIOCHEMICAL COMPOUNDS – BIOMEDIZINISCHE FORSCHUNGSREAGENZIEN GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| US-12419977-B2 | Radiopharmaceuticals | AdvanCell Isotopes Pty Limited (AU) | 2025-09-23 | — | — | US | disclosed |
| EP-4568985-A1 | RADIOPHARMACEUTICALS | Advancell Isotopes Pty Limited (AU) | 2025-06-18 | — | — | EP | disclosed |
| CN-119954773-A | PSMA compounds, pharmaceutical compositions comprising the same and uses thereof | 苏州威智创科生物有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025092841-A1 | PSMA COMPOUND, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | 山东威智知科药业有限公司 | 2025-05-08 | — | — | WO | disclosed |
| EP-4529473-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-20250064994-A1 | RADIOPHARMACEUTICALS | ADVANCELL IPCO US NO. 1 PTY LTD (AU) | 2025-02-27 | — | — | US | disclosed |
| EP-4464341-A2 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München, in Vertretung des Freistaates Bayern (DE) | 2024-11-20 | — | — | EP | disclosed |
| EP-4008359-B1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | UNIV MUENCHEN TECH (DE) | 2024-09-11 | — | — | EP | disclosed |
| EP-4255885-A1 | IODOTYROSINE DERIVATIVES AND PROCESS FOR PREPARING IODOTYROSINE DERIVATIVES | ABX Advanced Biochemical Compounds GmbH (DE) | 2023-10-11 | — | — | EP | disclosed |
| CN-116568694-A | Iodotyrosine derivative and method for preparing iodotyrosine derivative | 爱贝斯高级生化化合物-生物医学研究中心有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-113354709-B | Solid phase synthesis method of metastatic prostate cancer targeting drug precursor | 江苏华益科技有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-11497819-B2 | PSMA ligands for imaging and endoradiotherapy | Technische Universität München (DE) | 2022-11-15 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| EP-4008713-A1 | IODINE TYROSINE DERIVATIVES AND METHOD FOR THE PREPARATION OF IODINE TYROSINE DERIVATIVES | ABX Advanced Biochemical Compounds GmbH (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-4008359-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-3723815-B1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | UNIV MUENCHEN TECH (DE) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419977-B2 | Radiopharmaceuticals | KLK3, FOLH1, PSMA3 | FOLH1 2/4885ALB 1675/4885IL2 4788/4885 |
| US-20250319213-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | MARS1, MARS2, BCAT1 | FOLH1 27/4885ALB 524/4885IL2 3068/4885 |
| US-11497819-B2 | PSMA ligands for imaging and endoradiotherapy | KLK3, FOLH1, EEA1 | FOLH1 2/4885ALB 1225/4885IL2 4819/4885 |
| US-20250352678-A1 | RADIOPHARMACEUTICALS | KLK3, FOLH1, PSMA3 | FOLH1 2/4885ALB 1675/4885IL2 4788/4885 |
| US-20250064994-A1 | RADIOPHARMACEUTICALS | KLK3, FOLH1, PSMA3 | FOLH1 2/4885ALB 1675/4885IL2 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.